A clinical trial of the antibody Aducanumab, conducted by researchers at the University of Zurich (UZH), has yielded positive results, slowing cognitive decline in patients with early-stage Alzheimer's disease. Larger-scale trials of the treatment, which attacks the brain plaques central to the condition, are now underway, across 300 centers in 20 countries.
.. Continue Reading Positive results from antibody treatment in human Alzheimer's trialCategory: Medical
Tags: Related Articles:
- Protein discovery sheds light on brain sediment behind Alzheimer's disease
- Alzheimer's may be prevented by antibody-releasing implant
- Scientists successfully treat Alzheimer’s symptoms in mice
- Protein successfully combats Alzheimer's in mice
- Alzheimer's causes more diverse than previously thought
- Snake venom shapes as antidote for Alzheimer’s
from New Atlas http://ift.tt/2ctYQNi
No comments:
Post a Comment